Case Report: Successful treatment of mismatch repair-deficient cervical esophageal adenocarcinoma with immune checkpoint inhibition.

Aaron Dou, Chunzi Jenny Jin, Donna Maziak, Sebastien Gilbert, Jordan Sim, Eugene Leung, Moira Rushton

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aaron DouDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada.

Chunzi Jenny JinDepartment of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada.

Donna MaziakDepartment of Thoracic Surgery, University of Ottawa, Ottawa, ON, Canada.

Sebastien GilbertDepartment of Thoracic Surgery, University of Ottawa, Ottawa, ON, Canada.

Jordan SimDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada.

Eugene LeungDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada.

Moira RushtonDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical (upper) esophageal adenocarcinoma is an extremely rare, aggressive, and biologically distinct subtype of esophageal cancer, with few cases reported in literature. As such, pathophysiology and treatment approaches remain poorly understood. We report a case of a 39-year-old male diagnosed with a locally advanced, unresectable, MMR-deficient cervical esophageal adenocarcinoma driven by double somatic mutation of the MLH1 gene. He was treated with pseudocurative intent treatment through combining standard of care (chemotherapy and immunotherapy) with high-dose radiation therapy. The patient achieved complete remission with no evidence of disease recurrence over three years after initial diagnosis. This case highlights the complex decision making that is involved in the treatment of rare cancers for which data from large randomized controlled trials are not available, and the importance of integrating trial data, tumor pathogenesis, biomarkers, and patient preferences.

Indexed as

case reportesophageal cancerimmunotherapymicrosatellite instabilitymismatch repair deficiencyupper esophageal adenocarcinoma

Identifiers

PMID42052490

DOI10.3389/fonc.2026.1826912

PMCPMC13111040

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.